Results 71 to 80 of about 25,852 (233)

Platelet FcɣRIIa Expression Refines Clinical Risk Assessment After Myocardial Infarction

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background In patients with myocardial infarction (MI), quantifying expression of platelet FcɣRIIa (pFCG) stratifies risk of subsequent MI, stroke, and death. Aims Assess the prognostic implications of clinical risk alone and in combination with the pFCG test.
David J. Schneider, Sean R. McMahon, Dominick J. Angiolillo, Alexander C. Fanaroff, Homam Ibrahim, Patrick K. Hohl, Brett L. Wanamaker, Mark B. Effron, Peter M. DiBattiste, behalf of the investigators   +9 more
wiley   +1 more source

Genetic Determinants of P2Y12 Inhibitors and Clinical Implications [PDF]

Interventional Cardiology Clinics, 2017
There is significant interpatient variability in clopidogrel effectiveness, which is due in part to cytochrome P450 (CYP) 2C19 genotype. Approximately 30% of individuals carry CYP2C19 loss-of-function alleles, which have been consistently shown to reduce clopidogrel effectiveness after an acute coronary syndrome and percutaneous coronary intervention ...
Larisa H, Cavallari, Aniwaa Owusu, Obeng
openaire   +2 more sources

Intensified P2Y12 inhibition for high-on treatment platelet reactivity [PDF]

, 2020
High on treatment platelet reactivity (HPR) during treatment with clopidogrel has been consistently found to be strong risk factor for recurrent ischemic events after percutaneous coronary intervention (PCI).
Kreutz, Rolf P., Hugenberg, Daniel W., Mshelbwala, Fakilahyel S.   +2 more
core   +1 more source

Impact of CYP2C19 and CYP3A4 Inhibitor Use on Clopidogrel Clinical Effectiveness in CYP2C19 Genotyped Patients Undergoing Percutaneous Coronary Intervention

Clinical Pharmacology &Therapeutics, EarlyView.
CYP2C19 and CYP3A4 contribute to clopidogrel bioactivation. CYP2C19 no‐function alleles diminish clopidogrel's antiplatelet effects and clinical effectiveness. Coadministration of either a CYP2C19 or a CYP3A4 inhibitor may also reduce clopidogrel's antiplatelet effects and lead to phenoconversion in patients without a CYP2C19 no‐function allele (normal/
Danwei Shao, Jean G. Malavé, Joseph S. Rossi, Francesco Franchi, Ellen C. Keeley, Dominick J. Angiolillo, George A. Stouffer, Larisa H. Cavallari, Craig R. Lee   +8 more
wiley   +1 more source

РАННЕЕ НАЗНАЧЕНИЕ ИНГИБИТОРОВ P2Y12-РЕЦЕПТОРОВ ТРОМБОЦИТОВ БОЛЬНЫМ С ОСТРЫМ КОРОНАРНЫМ СИНДРОМОМ: ПОЛЬЗА ИЛИ ВРЕД? [PDF]

, 2018
Double antiplatelet therapy, which includes aspirin and platelet P2Y12 receptor inhibitors (hereinafter P2Y12 inhibitor) is the main component of treatment and secondary prevention after ACS.
Р. М. Шахнович, Roman M. Shakhnovich   +1 more
core   +2 more sources

P2Y12 inhibitor use predicts hematoma expansion in patients with intracerebral hemorrhage

Annals of Clinical and Translational Neurology
Objective Hematoma expansion (HE) predicts disability and death after acute intracerebral hemorrhage (ICH). Aspirin and anticoagulants have been associated with HE. We tested the hypothesis that P2Y12 inhibitors predict subsequent HE in patients.
Ethan J. Houskamp, Yuzhe Liu, Juliana Silva Pinheiro do Nascimento, Babak S. Jahromi, Paul F. Lindholm, Hau C. Kwaan, Andrew M. Naidech   +6 more
doaj   +1 more source

P2Y12 inhibitor monotherapy after complex percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials

Scientific Reports, 2023
It remains unknown whether the recent trend of short dual antiplatelet therapy (DAPT) followed by P2Y12 inhibitor monotherapy can simply be applied to patients undergoing complex percutaneous coronary intervention (PCI).
Yohei Sotomi, Yuki Matsuoka, Shungo Hikoso, Daisaku Nakatani, Katsuki Okada, Tomoharu Dohi, Hirota Kida, Bolrathanak Oeun, Akihiro Sunaga, Taiki Sato, Tetsuhisa Kitamura, Yasushi Sakata   +11 more
doaj   +1 more source

The in‐hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta‐analysis

ESC Heart Failure, Volume 12, Issue 2, Page 998-1012, April 2025.
In patients with Acute Myocardial Infarction related heart failure, the in‐hospital administration of ARNIs was associated with a reduced risk of MACEs and re‐hospitalizations for heart failure, as well as cardiac remodeling, compared to standard therapy.
Gianluca Di Pietro, Riccardo Improta, Paolo Severino, Andrea D'Amato, Lucia Ilaria Birtolo, Ovidio De Filippo, Antonio Lattanzio, Raffaele De Cristofaro, Giacchino Galardo, Fabrizio D'Ascenzo, Roberto Badagliacca, Gennaro Sardella, Maurizio Volterrani, Francesco Fedele, Carmine Dario Vizza, Massimo Mancone   +15 more
wiley   +1 more source

ADP exerts P2Y12 -dependent and P2Y12 -independent effects on primary human T cell responses to stimulation [PDF]

Journal of Cell Communication and Signaling, 2019
Purinergic signaling plays a complex role in inflammation. Nucleotides released by T lymphocytes, endothelial cells, and platelets during inflammation induce cellular responses by binding to receptors that regulate intracellular signaling pathways. Previous studies have found that purinergic signaling can have both proinflammatory and anti-inflammatory
Harika Vemulapalli, Samara Albayati, Viren C. Patwa, Douglas G. Tilley, Alexander Y. Tsygankov, Elisabetta Liverani   +5 more
openaire   +2 more sources

Pretreatment With P2Y12 Inhibitors in ST-Segment Elevation Myocardial Infarction: Insights From the Bern-PCI Registry. [PDF]

BACKGROUND Evidence to support immediate P2Y12 inhibitor loading in ST-segment elevation myocardial infarction (STEMI) is limited. OBJECTIVES This study sought to compare outcomes of STEMI patients receiving immediate or delayed P2Y12 inhibitor ...
Lanz, Jonas, Windecker, Stephan, Siontis, George Cm, Ye, Shirley Xinyu, Praz, Fabien, Shibutani, Hiroki, Otsuka, Tatsuhiko, Temperli, Fabrice, Stortecky, Stefan, Bär, Sarah, Losdat, Sylvain, Räber, Lorenz, Hunziker, Lukas, Pilgrim, Thomas, Bruno, Jolie, Kavaliauskaite, Raminta, Rohla, Miklos, Häner, Jonas D   +17 more
core   +1 more source